Myeloma Minute: Myeloma Disease News


| INNOVATION | Latest Research


Do two new blood disease cures have implications for multiple myeloma?

News this week of cures for a patient with HIV/AIDS and in sickle cell anemia raises the question: can these strategies be applied to multiple myeloma? IMF Chairman Brian G.M. Durie, MD walks us through the science at work in these new curative approaches, and says they illustrate “several related opportunities which can contribute to dramatically improved outcomes and even cures in the near future.”


| ACTION | Visit


You Have Spoken — the IMF Has Listened

We invite you to visit to experience its redesign and new features. Each step of the way, we have had patients, caregivers, family members, and healthcare professionals in mind. When you visit the Home Page, you will be greeted with these primary navigation buttons: What Is Multiple Myeloma? | Resources & Support | Our Research | Take Action.

You can also navigate based upon the options of Patient, Caregiver, or Healthcare Professional. Make sure to check out our new blog features, including a Hope Blog and a Cure Blog. Visit the new IMF website now.


| EDUCATION | Workshop


| EDUCATION | Seminar


Register Now for a Regional Community Workshop in Seattle, WA
Register Now for the IMF’s Patient & Family Seminar in Short Hills, NJ

The IMF will host a Regional Community Workshop at the Seattle Marriott Waterfront (2100 Alaskan Way) in Seattle on Saturday, April 6, 2019. Registration is FREE, but seating is limited. Learn from and meet one-on-one with myeloma experts to get answers to your questions and concerns.

The IMF Patient & Family Seminar in Short Hills, New Jersey, takes place April 5 - 6, 2019, at the Hilton Short Hills (41 JFK Parkway). During this seminar, learn about the latest treatments for and the management of multiple myeloma. The IMF Patient & Family Seminars are a wonderful opportunity to exchange valuable information, visit with friends, and share true-life experiences.

Register Now Button.png

Register Now Button.png

| ACTION | Advocacy


Cancer Drug Parity Act Reintroduced in the House and in the Senate

On March 12, 2019, the Cancer Drug Parity Act was reintroduced in the Senate (S. 741), and the House version (H.R. 1730) was reintroduced on March 13. The Act would correct an inequity in insurance benefit design between a patient’s prescription benefit and medical benefit. Despite the comparable costs, patients pay more out-of-pocket for their prescribed oral or self-injectable anticancer medication than patients who receive traditional IV treatments from their doctor. Patients who take an oral or self-injectable therapy often find themselves with high co-insurance, forcing them to pay up to 30% of the cost of their treatment. However, patients on traditional IV therapy have a low co-pay, typically $10 or $20.

Led by the IMF, the Coalition to Improve Access to Cancer Care (CIACC) has been working for the last 11 years on federal and state legislation to bring parity between the various delivery methods of anticancer treatment. For the 116th Congress, Senators Moran (R-KS), Wicker (R-MS), Smith (D-MN) and Murphy (D-CT) introduced the Senate version. Representatives Higgins (D-NY 26), Matsui (D-CA 6), Bilirakis (R-FL 12) and Guthrie (R-KY 2) introduced the House version. Forty-three states and the District of Columbia have passed some form of parity legislation. However, a federal bill is needed to cover the estimated 100 million people not affected by state insurance regulations. Visit for more information.


| INSPIRATION | Fundraiser


Register Now for the 2019 Miles for Myeloma 5K Run/Walk in Philadelphia

The Philadelphia Multiple Myeloma Networking Group hosts the 2019 Miles for Myeloma 5K Run/Walk at the Memorial Hall/Please Touch Museum (4231 Avenue of the Republic) in Philadelphia on Saturday, April 27, 2019. Day-of registration and check-in opens at 7:15 a.m. Online registration cut-off is at midnight on April 24, 2019.

Register Now Button.png

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



New isatuximab Clinical Trial: the IMROZ Study

New isatuximab Clinical Trial: the IKEMA Study

Join the conversation about myeloma on the Smart Patients Message Board

March 15-16, 2019
IMF Patient & Family Seminar
Boca Raton, FL

March 23, 2019
Regional Community Workshop
La Jolla, CA

April 5-6, 2019
IMF Patient & Family Seminar
Short Hills, NJ

April 6, 2019
Regional Community Workshop
Seattle, WA

April 27, 2019
2019 Miles for Myeloma 5K Run/Walk
Philadelphia, PA

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Celgene Corporation, Genentech, Sanofi-Genzyme, and Takeda Oncology
and individuals like you who supported the IMF this year

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.